Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. It focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1981
No trial phase data available
No trial data available
No trial data available
No approval data available
- Technology transfer is a pivotal milestone in cell therapy development, bridging laboratory-scale processes with GMP manufacturing for first-in-human clinical trials. - A new whitepaper from Evotec outlines key challenges including research-grade raw materials, equipment variability, and complex analytical assay implementation at receiving units. - Successful tech transfer safeguards product quality, ensures regulatory compliance, and forms the basis for process validation and ongoing continual improvement per ICH Q10 guidelines. - Poor execution of tech transfer can compromise patient safety and product quality, making strategic planning essential for small biotech companies with limited resources.
- Morepen Laboratories has secured a multi-year CDMO contract valued at approximately Rs. 825 crore ($91 million) from a global pharmaceutical company, marking one of the largest single mandates in the company's history. - The contract supplies are expected to begin within 4-5 months with execution scheduled through Q1 of the following financial year, leveraging Morepen's four decades of API manufacturing experience. - The mandate reflects growing confidence in Morepen's quality systems and regulatory compliance, with facilities accredited by USFDA, WHO-GMP and EU authorities. - This development positions Morepen to capitalize on the consolidating global pharmaceutical supply chain as companies seek compliant and scalable manufacturing partners.
- CHO Plus received a $10.4 million project agreement from BARDA's BioMaP Consortium to develop high productivity Chinese hamster ovary cell lines for manufacturing filovirus monoclonal antibodies over 30 months. - The company will partner with Avid Bioservices to scale up monoclonal antibody production for eventual industrial scale requirements to support biodefense initiatives. - The project focuses on producing therapeutic monoclonal antibodies against highly contagious and lethal filoviruses as part of BARDA's strategic biodefense preparedness efforts.
- Sharp Clinical has launched "Our Experience is Your Strength," a podcast series featuring seasoned experts discussing formulation, sterile manufacturing, clinical supplies, and commercial packaging challenges. - The series emphasizes that successful clinical trial timelines require comprehensive planning, with experts noting that "the secret to speed is planning" when working backwards from ambitious deadlines. - Episode discussions cover critical topics including API formulation development, clinical supply chain management, and the importance of cross-departmental coordination to avoid stockouts and delays. - Sharp's decades of CDMO experience inform strategies for just-in-time supply management, integrated IRT systems, and adaptive trial designs for rare diseases and orphan drugs.
- The global cell and gene therapy CDMO market is projected to grow from $8.07 billion in 2025 to $74.03 billion by 2034, expanding at a robust CAGR of 27.92% as demand for advanced therapies increases. - North America currently dominates the market with 67% share, while Asia Pacific is expected to grow fastest at a 29.03% CAGR due to strategic expansions and government support for regulatory frameworks. - Technological advancements including AI integration, automation, and decentralized manufacturing are transforming the CDMO landscape, with oncology applications representing 50% of the current market.
- Patient retention remains a critical challenge in clinical trials, with 30% dropout rates leading to increased costs and delayed market entry, as discussed at the OCT & CTS Nordics meeting in Copenhagen. - Digital tools and gamification strategies are emerging as effective solutions for improving patient engagement and retention, with experts emphasizing the importance of proper patient education in decentralized clinical trials. - The AAV vector manufacturing landscape is evolving into a buyer's market in 2024, with experts highlighting the need for careful CDMO partner selection and consideration of future commercial scaling requirements.
- The Asia-Pacific region has become a clinical trial powerhouse, contributing nearly 50% of new global trial activity and offering diverse patient demographics for expedited enrollment. - Clinical services organizations are helping pharmaceutical companies navigate complex regulatory requirements and cold-chain challenges, particularly for biologics and cell therapies. - The APAC clinical services/CDMO market is projected to reach $140 billion by 2031, driven by increasing demand for generic medicines and complex trial requirements.
